Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of ALV003 (latiglutenase) in symptomatic celiac disease on a gluten-free diet
2013-003660-31Phase 2Completed
- Sponsor
- Alvine Pharmaceuticals, Inc.
- Start
- Nov 2013
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of latiglutenase in celiac disease (4 arms), sponsored by Alvine Pharmaceuticals, Inc. Primary endpoint: Change in villus height to crypt depth ratio (Vh:Cd). Started Nov 2013; status: completed.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2013-003660-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003660-31.